Company intelligence / Profile preview

Idience

Seocho-gu, Seoul, South Koreaidience.com ↗

Ownership: Private
Development stage: Phase 1

Overview

IDX-1197, a PARP inhibitor, is currently under Phase 1a and Phase 1b/2a clinical studies targeting multiple solid tumors. It has demonstrated superior outcome potential compared to currently available PARP inhibitors in non-clinical studies[4].

Therapeutic areas: Oncology
Modalities: Small molecules (PARP inhibitor)
Industry: Biotech

Drug pipeline

3 assets

venadaparib

2 more assets in the full pipeline.

Request access →

Partnerships

Dong-A ST (strategic investment and joint research development agreement as of May 20, 2024)[6]

Beyond the preview

Go deeper on Idience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Idience.

Explore the full profile